Regeneron Pharmaceuticals (REGN)
(Delayed Data from NSDQ)
$1,031.15 USD
-14.83 (-1.42%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $1,056.00 +24.85 (2.41%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth A Momentum D VGM
Regeneron (REGN) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$1,182.43 | $1,300.00 | $805.00 | 13.05% |
Price Target
Based on short-term price targets offered by 23 analysts, the average price target for Regeneron comes to $1,182.43. The forecasts range from a low of $805.00 to a high of $1,300.00. The average price target represents an increase of 13.05% from the last closing price of $1,045.98.
Analyst Price Targets (23)
Broker Rating
Regeneron currently has an average brokerage recommendation (ABR) of 1.56 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 25 brokerage firms. The current ABR compares to an ABR of 1.48 a month ago based on 25 recommendations.
Of the 25 recommendations deriving the current ABR, 18 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 72% and 4% of all recommendations. A month ago, Strong Buy made up 76%, while Buy represented 4%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 18 | 19 | 19 | 19 | 19 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 5 | 4 | 4 | 5 | 5 |
Sell | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.56 | 1.48 | 1.48 | 1.54 | 1.54 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
9/24/2024 | SVB Securities | David Risinger | Strong Buy | Hold |
9/11/2024 | Not Identified | Not Identified | Hold | Hold |
8/2/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
8/2/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
8/2/2024 | Truist Securities | Srikripa Devarakonda | Strong Buy | Strong Buy |
8/2/2024 | Wells Fargo Securities | Mohit Bansal | Strong Buy | Strong Buy |
8/1/2024 | Piper Sandler | Christopher Raymond | Strong Buy | Strong Buy |
7/23/2024 | Cowen & Co. | Tyler Van Buren | Strong Buy | Strong Buy |
7/22/2024 | Cantor Fitzgerald & Co | Olivia Brayer | Hold | Hold |
7/19/2024 | BMO Capital Markets | Evan Seigerman | Strong Buy | Strong Buy |
7/18/2024 | Guggenheim Securities | Yatin Suneja | Strong Buy | Strong Buy |
7/12/2024 | UBS | Colin N Bristow | Strong Buy | Strong Buy |
7/10/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
7/9/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
6/27/2024 | Canaccord Genuity | John L Newman | Strong Buy | Strong Buy |
6/25/2024 | Argus Research Corp. | Jasper Hellweg | Strong Buy | Strong Buy |
6/18/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/20/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/13/2024 | Evercore Partners | Cory Kasimov | Not Available | Strong Buy |
3/31/2024 | Goldman Sachs | Salveen Richter | Strong Buy | Strong Buy |
2/5/2024 | Robert W. Baird & Co. | Brian P Skorney | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.56 |
ABR (Last week) | 1.48 |
# of Recs in ABR | 25 |
Average Target Price | $1,182.43 |
LT Growth Rate | 7.80% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 82 of 253 |
Current Quarter EPS Est: | 11.72 |
REGN FAQs
Regeneron Pharmaceuticals, Inc. (REGN) currently has an average brokerage recommendation (ABR) of 1.56 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 25 brokerage firms.
The average price target for Regeneron Pharmaceuticals, Inc. (REGN) is $#######. The current on short-term price targets is based on 12 reports.
The forecasts for Regeneron Pharmaceuticals, Inc. (REGN) range from a low of $805.001 to a high of $1300. The average price target represents a increase of $14.25 from the last closing price of $1031.15.
The current UPSIDE for Regeneron Pharmaceuticals, Inc. (REGN) is 14.25%
Based on short-term price targets offered by 23 analysts, the average price target for Regeneron comes to $1,182.43. The forecasts range from a low of $805.00 to a high of $1,300.00. The average price target represents an increase of 13.05% from the last closing price of $1,045.98.